Want to see HK:0690 full AI Analyst Report?
0690 Stock Chart & Stats
HK$0.13
>-HK$0.01(-3.17%)
At close: 4:00 PM EST
HK$0.13
>-HK$0.01(-3.17%)
Day’s Range― - ―
52-Week RangeHK$0.07 - HK$0.17
Previous CloseN/A
Volume1.74M
Average Volume (3M)5.61M
Market Cap
HK$452.74M
Enterprise ValueHK$443.33M
Total Cash (Recent Filing)HK$179.89M
Total Debt (Recent Filing)HK$97.76M
Price to Earnings (P/E)4.9
Beta-0.06
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.12%
Share Statistics
EPS (TTM)0.02
Shares Outstanding5,971,228,000
10 Day Avg. Volume4,310,360
30 Day Avg. Volume5,609,336
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)1.66
Price to Sales (P/S)1.17
P/FCF Ratio18.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross & Operating MarginsSustained gross margins in the low-80% range and mid-teens operating/net margins indicate persistent product-level profitability and pricing power. These margins support durable cash generation, fund R&D and commercialization, and provide buffers versus industry cost pressures over months.
Strong ROE And Profitability TurnaroundA multi-year shift from losses to consistent profitability and ROE in the low-to-mid 20% range shows efficient capital utilization. This enduring improvement underpins reinvestment capacity, supports dividend policy, and signals management effectiveness in allocating capital over the medium term.
Consistent Positive Cash GenerationPositive operating cash flow since 2021 and consecutive free cash flow through 2025 demonstrate an improving ability to convert operations into spendable cash. This trend supports durability for capex, dividends, or deleveraging even if revenue growth moderates over several quarters.
Bears Say
Sharp 2025 Revenue DeclineA ~57% revenue drop in 2025 signals material demand, product mix, or commercialization issues that can persist beyond a quarter. Such a decline threatens utilization, long-term earnings resilience, and the sustainability of margins and cash flows if recovery is slow or market share is lost.
Uneven Cash ConversionHistorically weak cash-to-earnings conversion and missing/unclear 2025 cash-flow ratios reduce confidence that accounting profits translate into durable liquidity. This raises risk that earnings cannot reliably fund capex, dividends or debt service if headwinds persist.
Uptick In Absolute Debt LevelsAn increase in absolute debt, even with modest debt-to-equity, can constrain flexibility if revenues and cash flows weaken. Higher nominal obligations raise refinancing and interest risks and may limit the company's ability to invest in R&D, manufacturing scale, or respond to market setbacks.
Uni-Bio Science Group Ltd. News
0690 FAQ
What was Uni-Bio Science Group Ltd.’s price range in the past 12 months?
Uni-Bio Science Group Ltd. lowest stock price was HK$0.07 and its highest was HK$0.17 in the past 12 months.
What is Uni-Bio Science Group Ltd.’s market cap?
Uni-Bio Science Group Ltd.’s market cap is HK$452.74M.
When is Uni-Bio Science Group Ltd.’s upcoming earnings report date?
Uni-Bio Science Group Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 24 days.
How were Uni-Bio Science Group Ltd.’s earnings last quarter?
Uni-Bio Science Group Ltd. released its earnings results on Mar 27, 2026. The company reported HK$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.003.
Is Uni-Bio Science Group Ltd. overvalued?
According to Wall Street analysts Uni-Bio Science Group Ltd.’s price is currently Overvalued.
Does Uni-Bio Science Group Ltd. pay dividends?
Uni-Bio Science Group Ltd. pays a Notavailable dividend of HK$0.003 which represents an annual dividend yield of 4.12%. See more information on Uni-Bio Science Group Ltd. dividends here
What is Uni-Bio Science Group Ltd.’s EPS estimate?
Uni-Bio Science Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Uni-Bio Science Group Ltd. have?
Uni-Bio Science Group Ltd. has 5,971,228,000 shares outstanding.
What happened to Uni-Bio Science Group Ltd.’s price movement after its last earnings report?
Uni-Bio Science Group Ltd. reported an EPS of HK$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.636%.
Which hedge fund is a major shareholder of Uni-Bio Science Group Ltd.?
Currently, no hedge funds are holding shares in HK:0690
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Uni-Bio Science Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.30%
12-Months-Change
Fundamentals
Return on Equity
4.12%
Trailing 12-Months
Asset Growth
12.03%
Trailing 12-Months
Company Description
Uni-Bio Science Group Ltd.
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Technical Analysis
Brii Biosciences Limited
―
Genor Biopharma Holdings Limited
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Wuhan YZY Biopharma Co., Ltd. Class H
―